Why Trillium (Nasdaq: TRIL) Stock Is a Buy After Earnings

Trillium Therapeutics Inc. (Nasdaq: TRIL) stock has dipped nearly 5% in the last week after the company reported a Q2 earnings loss of $0.80. Analysts had been predicting a loss of $0.75 for the quarter. In the past three months, TRIL stock has now dipped 16.4%, and the poor earnings report only stoked the fears of nervous investors. But despite its recent performance, TRIL stock is still one of the best biotech stocks to buy now. All because of this incredible cancer treatment... Tags: biotech stocks , biotech stocks to buy , Nasdaq: TRIL , TRIL earnings , TRIL stock , TRIL stock price , TRILLIUM , Trillium earnings , Trillium stock , Trillium stock price To get full access to all Money Morning content, click here About Money Morning: Money Morning gives you access to a team of ten market experts with more than 250 years of combined investing experience – for free . Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors. Disclaimer: © 2015 Money Morning and Money Map Press. All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning. 16 W. Madison St. Baltimore, MD, 21201. The post Why Trillium (Nasdaq: TRIL) Stock Is a Buy After Earnings appeared first on Money Morning - We Make Investing Profitable .